Synovial Sarcoma Clinical Trial
Official title:
A Pilot Study to Test Whether Systemic Interferon Gamma Increases Tumor Class I MHC Expression in Patients With Synovial Sarcoma and Myxoid/Round Cell Liposarcoma
This pilot clinical trial studies the effect of recombinant interferon gamma on tissue in treating patients with soft tissue sarcoma. Interferon gamma may interfere with the growth of tumor cells.
PRIMARY OBJECTIVES:
I. To determine whether systemic administration of interferon (IFN) gamma (recombinant
interferon gamma) will increase class I major histocompatibility complex (MHC) expression in
synovial sarcoma (SS) and myxoid/round cell liposarcoma (MRCL) tumors.
SECONDARY OBJECTIVES:
I. To determine whether systemic administration of IFN gamma will increase class II MHC
expression in SS and MRCL tumors.
II. To examine changes in the immune response to MRCL and SS by examining changes in the
immune infiltrates, antibody response and antigen specific T cell response before and after
IFN gamma treatment.
OUTLINE:
Patients receive recombinant interferon gamma subcutaneously (SC) every 7 days for 4 weeks
before surgery.
After completion of study, patients are followed up at 2 weeks post-surgery.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT03399448 -
NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)
|
Phase 1 | |
| Withdrawn |
NCT04906876 -
A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas
|
Phase 2 | |
| Active, not recruiting |
NCT02869217 -
Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors
|
Phase 1 | |
| Completed |
NCT01674101 -
Effects of Preoperative Physical Therapy in Patients With Lower Extremity Malignancy
|
N/A | |
| Completed |
NCT03250325 -
Study of TBI-1301 (NY-ESO-1 T Cell Receptor Gene Transduced Autologous T Lymphocytes) in Patients With Synovial Sarcoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06094101 -
Personalized Vaccination in Fusion+ Sarcoma Patients (PerVision)
|
Phase 1/Phase 2 | |
| Terminated |
NCT03520959 -
A Phase 3, Randomized, Double-blind, Placebo-controlled Study For Subjects With Locally-advanced Unresectable or Metastatic Synovial Sarcoma (V943-003, IMDZ-04-1702)
|
Phase 3 | |
| Terminated |
NCT02683148 -
DHEA in Synovial Sarcoma Patients
|
Phase 1 | |
| Recruiting |
NCT05642455 -
SPEARHEAD-3 Pediatric Study
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04420975 -
Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma
|
Phase 1 | |
| Recruiting |
NCT02983539 -
Detection of Circulating Tumor Cells in Patients With Sarcomas
|
||
| Recruiting |
NCT04028479 -
The Registry of Oncology Outcomes Associated With Testing and Treatment
|
||
| Active, not recruiting |
NCT03132922 -
MAGE-A4ᶜ¹º³²T for Multi-Tumor
|
Phase 1 | |
| Terminated |
NCT04145700 -
CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial Sarcoma
|
Phase 1/Phase 2 | |
| Completed |
NCT00004853 -
Comparison of Filgrastim and Filgrastim SD/01in Boosting White Cell Counts After Intensive Chemotherapy
|
Phase 1 | |
| Suspended |
NCT06083883 -
Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1
|
Phase 1 | |
| Terminated |
NCT05355753 -
A Study to Assess the Safety and Tolerability of CFT8634 in Locally Advanced or Metastatic SMARCB1-Perturbed Cancers, Including Synovial Sarcoma and SMARCB1-Null Tumors
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT05116800 -
Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma
|
Phase 2 | |
| Recruiting |
NCT03638206 -
Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
|
Phase 1/Phase 2 | |
| Terminated |
NCT00140855 -
A Study of Anti-CTLA-4 Antibody in Patients With Advanced Synovial Sarcoma
|
Phase 2 |